Tao Capital Management LP
Long book
$118.8M
Q1 2026
Positions
8
Top-10 weight
100%
concentration
Last quarter
+68.2%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsTao Capital Management LP is a concentrated fundamental stock-picker, running a $118.8M US long book across 8 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: TWIST BIOSCIENCE CORP, TESLA INC, OUSTER INC, MADRIGAL PHARMACEUTICALS INC, HYATT HOTELS CORP - CL A.
Over the last 9 quarters its long book ran on average 9.9pp per quarter ahead of the S&P 500, beating the index in 6 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+15.7%
Q2 2024
-9.6%
Q3 2024
+29.8%
Q4 2024
-14.8%
Q1 2025
+17.4%
Q2 2025
+19.3%
Q3 2025
+1.3%
Q4 2025
+2.3%
Q1 2026
+68.2%
Sector allocation
Healthcare 49%
Industrials 40%
Services media 8%
Other 3%
Long book by quarter
What does Tao Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| TWST TWIST BIOSCIENCE CORP | Healthcare | 828.8K | $39.4M | 33.1% | Held |
| TSLA TESLA INC | Industrials | 86.3K | $32.1M | 27.0% | Held |
| OUST OUSTER INC | Industrials | 845.3K | $15.5M | 13.1% | Held |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 21.0K | $11.0M | 9.3% | Held |
| H HYATT HOTELS CORP - CL A | Services media | 70.0K | $10.1M | 8.5% | Held |
| TXG 10X GENOMICS INC-CLASS A | Healthcare | 210.9K | $4.5M | 3.8% | Held |
| MASS 908 DEVICES INC | Other | 569.0K | $3.5M | 2.9% | Held |
| WRBY WARBY PARKER INC-CLASS A | Healthcare | 134.5K | $2.8M | 2.4% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 8 | $118.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 8 | $116.2M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 10 | $132.2M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 12, 2025 | 9 | $136.4M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 12, 2025 | 9 | $116.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 10 | $143.3M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 8, 2024 | 10 | $110.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 7, 2024 | 10 | $122.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 9, 2024 | 10 | $105.5M | canonical | SEC ↗ |
Similar funds
Sanders Capital, LLCGATES FOUNDATION TRUSTEAGLE CAPITAL MANAGEMENT LLCWoodbridge Co LtdAlecta Tjanstepension OmsesidigtMubadala Investment Co PJSCH&H International Investment, LLCNewlands Management Operations LLCINVESTOR ABIndependent Franchise Partners LLPPineStone Asset Management Inc.Pentwater Capital Management LP